Government caps trade margins on 137 cancer drugs; questions remain on bill reductions

The government has imposed a ceiling on trade margins for 137 cancer drugs, aimed at restraining what distributors and retailers can add to the price of these medicines. Officials and analysts, however, are questioning whether the move will translate into lower bills for patients. The concern is that margin caps alone may not fully pass savings through the supply chain to end consumers. The article examines how the measure may affect affordability for cancer patients and what further steps could be needed to ensure real cost reductions.